{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:45:42Z","timestamp":1765547142632,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Future Medical Youth Innovation Team Program of Chongqing Medical University","award":["W0043"],"award-info":[{"award-number":["W0043"]}]},{"name":"Chongqing chief expert studio project, China\uff0cYoung and Middle-aged Medical Excellence Team Program of Chongqing, and Chongqing Talent Program","award":["CQYC202005013"],"award-info":[{"award-number":["CQYC202005013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10072-023-07186-w","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T04:27:48Z","timestamp":1699504068000},"page":"1707-1717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Wei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanxin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-2922","authenticated-orcid":false,"given":"Fei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"7186_CR1","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","volume":"19","author":"S Muppidi","year":"2020","unstructured":"Muppidi S, Guptill JT, Jacob S et al (2020) COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 19:970\u2013971. https:\/\/doi.org\/10.1016\/S1474-4422(20)30413-0","journal-title":"Lancet Neurol"},{"key":"7186_CR2","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/ene.14951","volume":"28","author":"M Jakub\u00edkov\u00e1","year":"2021","unstructured":"Jakub\u00edkov\u00e1 M, T\u00fdblov\u00e1 M, Tesa\u0159 A et al (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28:3418\u20133425. https:\/\/doi.org\/10.1111\/ene.14951","journal-title":"Eur J Neurol"},{"key":"7186_CR3","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","volume":"96","author":"G Sol\u00e9","year":"2021","unstructured":"Sol\u00e9 G, Mathis S, Friedman D et al (2021) Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology 96:e2109\u2013e2120. https:\/\/doi.org\/10.1212\/WNL.0000000000011669","journal-title":"Neurology"},{"key":"7186_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara A, Undurraga EA, Gonz\u00e1lez C et al (2021) Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med 385:875\u2013884. https:\/\/doi.org\/10.1056\/NEJMoa2107715","journal-title":"N Engl J Med"},{"key":"7186_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/vaccines9101112","volume":"9","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Tang Y, Li C et al (2021) COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series. Vaccines (Basel) 9:1112. https:\/\/doi.org\/10.3390\/vaccines9101112","journal-title":"Vaccines (Basel)"},{"key":"7186_CR6","doi-asserted-by":"publisher","first-page":"733418","DOI":"10.3389\/fimmu.2021.733418","volume":"12","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Zhou R, Yang H, Yang H (2021) To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis. Front Immunol 12:733418. https:\/\/doi.org\/10.3389\/fimmu.2021.733418","journal-title":"Front Immunol"},{"key":"7186_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.nmd.2022.01.013","volume":"32","author":"I Lotan","year":"2022","unstructured":"Lotan I, Hellmann MA, Friedman Y et al (2022) Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. Neuromuscul Disord 32:230\u2013235. https:\/\/doi.org\/10.1016\/j.nmd.2022.01.013","journal-title":"Neuromuscul Disord"},{"key":"7186_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/neurolint14020033","volume":"14","author":"A Lupica","year":"2022","unstructured":"Lupica A, Di Stefano V, Iacono S et al (2022) Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort. Neurol Int 14:406\u2013416. https:\/\/doi.org\/10.3390\/neurolint14020033","journal-title":"Neurol Int"},{"issue":"8","key":"7186_CR9","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","volume":"269","author":"G Sansone","year":"2022","unstructured":"Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269(8):3965\u20133981. https:\/\/doi.org\/10.1007\/s00415-022-11140-9","journal-title":"J Neurol"},{"key":"7186_CR10","doi-asserted-by":"publisher","first-page":"923017","DOI":"10.3389\/fimmu.2022.923017","volume":"13","author":"H-Y Li","year":"2022","unstructured":"Li H-Y, Shao L-Y, Song M et al (2022) Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study. Front Immunol 13:923017. https:\/\/doi.org\/10.3389\/fimmu.2022.923017","journal-title":"Front Immunol"},{"issue":"8","key":"7186_CR11","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/ene.15348","volume":"29","author":"A Farina","year":"2022","unstructured":"Farina A, Falso S, Cornacchini S et al (2022) Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience. Eur J Neurol 29(8):2505\u20132510. https:\/\/doi.org\/10.1111\/ene.15348","journal-title":"Eur J Neurol"},{"key":"7186_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/mus.27703","volume":"66","author":"J Gamez","year":"2022","unstructured":"Gamez J, Gamez A, Carmona F (2022) Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis. Muscle Nerve 66:612\u2013617. https:\/\/doi.org\/10.1002\/mus.27703","journal-title":"Muscle Nerve"},{"key":"7186_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mus.27657","volume":"66","author":"A Urra Pincheira","year":"2022","unstructured":"Urra Pincheira A, Alnajjar S, Katzberg H et al (2022) Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. Muscle Nerve 66:558\u2013561. https:\/\/doi.org\/10.1002\/mus.27657","journal-title":"Muscle Nerve"},{"key":"7186_CR14","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1007\/s00415-022-11303-8","volume":"269","author":"A Doron","year":"2022","unstructured":"Doron A, Piura Y, Vigiser I et al (2022) BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves. J Neurol 269:6193\u20136201. https:\/\/doi.org\/10.1007\/s00415-022-11303-8","journal-title":"J Neurol"},{"key":"7186_CR15","doi-asserted-by":"publisher","unstructured":"Wang HY, Qiu L, Ou CY et al (2023) An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis. Neurol Sci 1\u20137. https:\/\/doi.org\/10.1007\/s10072-023-06811-y","DOI":"10.1007\/s10072-023-06811-y"},{"key":"7186_CR16","doi-asserted-by":"publisher","first-page":"1141983","DOI":"10.3389\/fimmu.2023.1141983","volume":"14","author":"Z Ruan","year":"2023","unstructured":"Ruan Z, Huan X, Su Y et al (2023) Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study. Front Immunol 14:1141983. https:\/\/doi.org\/10.3389\/fimmu.2023.1141983","journal-title":"Front Immunol"},{"key":"7186_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","volume":"183","author":"H Yao","year":"2020","unstructured":"Yao H, Song Y, Chen Y et al (2020) Molecular Architecture of the SARS-CoV-2 Virus. Cell 183:730-738.e13. https:\/\/doi.org\/10.1016\/j.cell.2020.09.018","journal-title":"Cell"},{"key":"7186_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/CM9.0000000000000722","volume":"133","author":"L-L Ren","year":"2020","unstructured":"Ren L-L, Wang Y-M, Wu Z-Q et al (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 133:1015\u20131024. https:\/\/doi.org\/10.1097\/CM9.0000000000000722","journal-title":"Chin Med J (Engl)"},{"key":"7186_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, Lee J-Y, Yang J-S et al (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell 181:914-921.e10. https:\/\/doi.org\/10.1016\/j.cell.2020.04.011","journal-title":"Cell"},{"key":"7186_CR20","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J, Wan Y, Luo C et al (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117:11727\u201311734. https:\/\/doi.org\/10.1073\/pnas.2003138117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7186_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41594-020-0483-8","volume":"27","author":"M McCallum","year":"2020","unstructured":"McCallum M, Walls AC, Bowen JE et al (2020) Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol 27:942\u2013949. https:\/\/doi.org\/10.1038\/s41594-020-0483-8","journal-title":"Nat Struct Mol Biol"},{"key":"7186_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.gendis.2020.07.006","volume":"7","author":"J Hu","year":"2020","unstructured":"Hu J, Gao Q, He C et al (2020) Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis 7:551\u2013557. https:\/\/doi.org\/10.1016\/j.gendis.2020.07.006","journal-title":"Genes Dis"},{"key":"7186_CR23","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie J, Li Q, Wu J et al (2020) Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15:3699\u20133715. https:\/\/doi.org\/10.1038\/s41596-020-0394-5","journal-title":"Nat Protoc"},{"key":"7186_CR24","doi-asserted-by":"publisher","first-page":"E1011","DOI":"10.3390\/v12091011","volume":"12","author":"I Hyseni","year":"2020","unstructured":"Hyseni I, Molesti E, Benincasa L et al (2020) Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses 12:E1011. https:\/\/doi.org\/10.3390\/v12091011","journal-title":"Viruses"},{"key":"7186_CR25","doi-asserted-by":"publisher","first-page":"e1963","DOI":"10.1002\/rmv.1963","volume":"28","author":"Q Li","year":"2018","unstructured":"Li Q, Liu Q, Huang W et al (2018) Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol 28:e1963. https:\/\/doi.org\/10.1002\/rmv.1963","journal-title":"Rev Med Virol"},{"key":"7186_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1080\/21645515.2017.1325050","volume":"13","author":"L Zhang","year":"2017","unstructured":"Zhang L, Li Q, Liu Q et al (2017) A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother 13:1811\u20131817. https:\/\/doi.org\/10.1080\/21645515.2017.1325050","journal-title":"Hum Vaccin Immunother"},{"key":"7186_CR27","doi-asserted-by":"publisher","first-page":"e99905","DOI":"10.1371\/journal.pone.0099905","volume":"9","author":"B Wang","year":"2014","unstructured":"Wang B, Wang B, Liu P et al (2014) Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection. PLoS ONE 9:e99905. https:\/\/doi.org\/10.1371\/journal.pone.0099905","journal-title":"PLoS ONE"},{"key":"7186_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"7186_CR29","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/acn3.50901","volume":"6","author":"SM Raja","year":"2019","unstructured":"Raja SM, Howard JF, Juel VC et al (2019) Clinical outcome measures following plasma exchange for MG exacerbation. Ann Clin Transl Neurol 6:2114\u20132119. https:\/\/doi.org\/10.1002\/acn3.50901","journal-title":"Ann Clin Transl Neurol"},{"key":"7186_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ebiom.2018.01.007","volume":"28","author":"B Tackenberg","year":"2018","unstructured":"Tackenberg B, Schneider M, Blaes F et al (2018) Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine 28:143\u2013150. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.007","journal-title":"EBioMedicine"},{"key":"7186_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.autrev.2008.07.008","volume":"8","author":"N Toplak","year":"2008","unstructured":"Toplak N, Kveder T, Trampus-Bakija A et al (2008) Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 8:134\u2013138. https:\/\/doi.org\/10.1016\/j.autrev.2008.07.008","journal-title":"Autoimmun Rev"},{"key":"7186_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol 11:212. https:\/\/doi.org\/10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"7186_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cca.2022.06.017","volume":"533","author":"K Shao","year":"2022","unstructured":"Shao K, Yue Y-X, Zhao L-M et al (2022) Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients. Clin Chim Acta 533:122\u2013130. https:\/\/doi.org\/10.1016\/j.cca.2022.06.017","journal-title":"Clin Chim Acta"},{"key":"7186_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693\u2013699. https:\/\/doi.org\/10.1002\/mus.26689","journal-title":"Muscle Nerve"},{"key":"7186_CR35","doi-asserted-by":"publisher","first-page":"e239834","DOI":"10.1001\/jamanetworkopen.2023.9834","volume":"6","author":"M Alcantara","year":"2023","unstructured":"Alcantara M, Koh M, Park AL et al (2023) Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis. JAMA Netw Open 6:e239834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.9834","journal-title":"JAMA Netw Open"},{"key":"7186_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG et al (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91:392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7186_CR37","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"27","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro AC, Aikawa NE, Saad CGS et al (2021) Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 27:1744\u20131751. https:\/\/doi.org\/10.1038\/s41591-021-01469-5","journal-title":"Nat Med"},{"key":"7186_CR38","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2665-9913(21)00327-1","volume":"4","author":"NE Aikawa","year":"2022","unstructured":"Aikawa NE, Kupa LVK, Pasoto SG et al (2022) Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatol 4:e113\u2013e124. https:\/\/doi.org\/10.1016\/S2665-9913(21)00327-1","journal-title":"Lancet Rheumatol"},{"key":"7186_CR39","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.jtauto.2021.100114","volume":"4","author":"LC Plymate","year":"2021","unstructured":"Plymate LC, Pepper G, Krist MP, Koelle DM (2021) Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. J Transl Autoimmun 4:100114. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100114","journal-title":"J Transl Autoimmun"},{"key":"7186_CR40","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/annrheumdis-2021-220993","volume":"80","author":"B Golding","year":"2021","unstructured":"Golding B, Lee Y, Golding H, Khurana S (2021) Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report. Ann Rheum Dis 80:1359\u20131361. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220993","journal-title":"Ann Rheum Dis"},{"key":"7186_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586:516\u2013527. https:\/\/doi.org\/10.1038\/s41586-020-2798-3","journal-title":"Nature"},{"key":"7186_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0072-9752(07)01505-9","volume":"91","author":"N Sommer","year":"2008","unstructured":"Sommer N, Tackenberg B, Hohlfeld R (2008) The immunopathogenesis of myasthenia gravis. Handb Clin Neurol 91:169\u2013212. https:\/\/doi.org\/10.1016\/S0072-9752(07)01505-9","journal-title":"Handb Clin Neurol"},{"key":"7186_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/0961203311429554","volume":"21","author":"ES Vista","year":"2012","unstructured":"Vista ES, Crowe SR, Thompson LF et al (2012) Influenza vaccination can induce new-onset anticardiolipins but not \u03b22-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus 21:168\u2013174. https:\/\/doi.org\/10.1177\/0961203311429554","journal-title":"Lupus"},{"key":"7186_CR44","doi-asserted-by":"publisher","first-page":"666046","DOI":"10.3389\/fimmu.2021.666046","volume":"12","author":"Y Cai","year":"2021","unstructured":"Cai Y, Han L, Zhu D et al (2021) A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis. Front Immunol 12:666046. https:\/\/doi.org\/10.3389\/fimmu.2021.666046","journal-title":"Front Immunol"},{"key":"7186_CR45","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.3390\/diagnostics11112098","volume":"11","author":"CM Gambino","year":"2021","unstructured":"Gambino CM, Agnello L, Lo Sasso B et al (2021) Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Enzyme-Linked Immunosorbent Assay for Diagnosing Myasthenia Gravis. Diagnostics (Basel) 11:2098. https:\/\/doi.org\/10.3390\/diagnostics11112098","journal-title":"Diagnostics (Basel)"},{"key":"7186_CR46","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/22221751.2022.2044271","volume":"11","author":"X Yu","year":"2022","unstructured":"Yu X, Qi X, Cao Y et al (2022) Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant. Emerg Microbes Infect 11:749\u2013752. https:\/\/doi.org\/10.1080\/22221751.2022.2044271","journal-title":"Emerg Microbes Infect"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07186-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T07:25:36Z","timestamp":1710487536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07186-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7186"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07186-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective observational cohort study was performed at the First Affiliated Hospital of Chongqing Medical University and approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (2021\u2013296).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate and publication from the patient was also obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}